Switch to:
Also traded in: Canada, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.02
NYSE:VRX's Cash to Debt is ranked lower than
97% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. NYSE:VRX: 0.02 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:VRX' s Cash to Debt Range Over the Past 10 Years
Min: -1.06  Med: 0.18 Max: No Debt
Current: 0.02
-1.06
No Debt
Equity to Asset 0.09
NYSE:VRX's Equity to Asset is ranked lower than
96% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NYSE:VRX: 0.09 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:VRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.09  Med: 0.51 Max: 0.85
Current: 0.09
0.09
0.85
F-Score: 4
Z-Score: 0.17
M-Score: -2.97
WACC vs ROIC
6.75%
-1.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) -5.35
NYSE:VRX's Operating margin (%) is ranked lower than
77% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.25 vs. NYSE:VRX: -5.35 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:VRX' s Operating margin (%) Range Over the Past 10 Years
Min: -9.32  Med: 15.51 Max: 24.38
Current: -5.35
-9.32
24.38
Net-margin (%) -22.65
NYSE:VRX's Net-margin (%) is ranked lower than
81% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NYSE:VRX: -22.65 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:VRX' s Net-margin (%) Range Over the Past 10 Years
Min: -22.65  Med: 8.65 Max: 26.4
Current: -22.65
-22.65
26.4
ROE (%) -41.48
NYSE:VRX's ROE (%) is ranked lower than
86% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.55 vs. NYSE:VRX: -41.48 )
Ranked among companies with meaningful ROE (%) only.
NYSE:VRX' s ROE (%) Range Over the Past 10 Years
Min: -41.48  Med: 8.21 Max: 17.73
Current: -41.48
-41.48
17.73
ROA (%) -4.74
NYSE:VRX's ROA (%) is ranked lower than
73% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. NYSE:VRX: -4.74 )
Ranked among companies with meaningful ROA (%) only.
NYSE:VRX' s ROA (%) Range Over the Past 10 Years
Min: -4.74  Med: 2.36 Max: 13.02
Current: -4.74
-4.74
13.02
ROC (Joel Greenblatt) (%) -21.30
NYSE:VRX's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.88 vs. NYSE:VRX: -21.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:VRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -69.93  Med: 73.54 Max: 144.06
Current: -21.3
-69.93
144.06
Revenue Growth (3Y)(%) 54.70
NYSE:VRX's Revenue Growth (3Y)(%) is ranked higher than
96% of the 609 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. NYSE:VRX: 54.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:VRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.8  Med: 27.2 Max: 55.3
Current: 54.7
-10.8
55.3
EBITDA Growth (3Y)(%) 66.80
NYSE:VRX's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.60 vs. NYSE:VRX: 66.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:VRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.7  Med: 14.5 Max: 113.3
Current: 66.8
-35.7
113.3
EPS Growth (3Y)(%) 45.80
NYSE:VRX's EPS Growth (3Y)(%) is ranked higher than
90% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. NYSE:VRX: 45.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:VRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.1  Med: 11.5 Max: 81
Current: 45.8
-37.1
81
» NYSE:VRX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-15)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

VRX Guru Trades in Q4 2015

Steven Cohen 17,900 sh (New)
Jana Partners 1,565,935 sh (New)
Chris Davis 3,784,012 sh (+150.74%)
Diamond Hill Capital 301,374 sh (+77.76%)
Andreas Halvorsen 7,793,397 sh (+56.08%)
First Eagle Investment 1,640,132 sh (+55.41%)
John Paulson 13,265,900 sh (+49.22%)
Lou Simpson 2,698,614 sh (+38.18%)
Private Capital 336,306 sh (+13.26%)
Glenn Greenberg 6,252,331 sh (+12.09%)
Ruane Cunniff 35,375,610 sh (+4.28%)
First Eagle Investment 2,500 sh (unchged)
First Eagle Investment 2,000 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
Ken Fisher Sold Out
Leon Cooperman Sold Out
Wallace Weitz Sold Out
Lee Ainslie Sold Out
Joel Greenblatt Sold Out
Bill Ackman 16,591,122 sh (-14.80%)
Steve Mandel 5,829,079 sh (-21.88%)
Jeremy Grantham 4,393,848 sh (-46.26%)
» More
Q1 2016

VRX Guru Trades in Q1 2016

Arnold Schneider 66,000 sh (New)
David Tepper 945,000 sh (New)
Joel Greenblatt 15,088 sh (New)
Francis Chou 976,843 sh (New)
Signature Select Canadian Fund 153,900 sh (New)
Steven Cohen 3,574,900 sh (+19871.51%)
Chris Davis 7,240,337 sh (+91.34%)
Diamond Hill Capital 571,305 sh (+89.57%)
Bill Ackman 21,591,122 sh (+30.14%)
Private Capital 342,916 sh (+1.97%)
John Paulson 13,284,800 sh (+0.14%)
First Eagle Investment 11,970 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
John Paulson 73,100 sh (unchged)
John Paulson 169,800 sh (unchged)
Steven Cohen 529,600 sh (unchged)
Jeremy Grantham Sold Out
Jana Partners Sold Out
Andreas Halvorsen Sold Out
Steve Mandel Sold Out
Lou Simpson 2,591,399 sh (-3.97%)
First Eagle Investment 1,495,332 sh (-8.83%)
Ruane Cunniff 30,308,449 sh (-14.32%)
Glenn Greenberg 2,034,281 sh (-67.46%)
» More
Q2 2016

VRX Guru Trades in Q2 2016

Jim Simons 111,889 sh (New)
Francis Chou 1,446,843 sh (+48.11%)
John Paulson 19,072,000 sh (+43.56%)
Steven Cohen 3,834,400 sh (+7.26%)
Chris Davis 7,304,762 sh (+0.89%)
Bill Ackman 21,591,122 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
Steven Cohen 1,430,000 sh (unchged)
David Tepper Sold Out
Glenn Greenberg Sold Out
Arnold Schneider Sold Out
Joel Greenblatt Sold Out
Diamond Hill Capital 557,933 sh (-2.34%)
Lou Simpson 2,427,903 sh (-6.31%)
Private Capital 308,142 sh (-10.14%)
First Eagle Investment 380,900 sh (-74.53%)
Ruane Cunniff 446,442 sh (-98.53%)
» More
Q3 2016

VRX Guru Trades in Q3 2016

Jim Simons 432,489 sh (+286.53%)
Steven Cohen 4,621,300 sh (+20.52%)
Private Capital 347,368 sh (+12.73%)
Chris Davis 7,365,210 sh (+0.83%)
Francis Chou 1,446,843 sh (unchged)
First Eagle Investment 380,900 sh (unchged)
Steven Cohen 1,430,000 sh (unchged)
Bill Ackman 21,591,122 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
Lou Simpson Sold Out
John Paulson 18,871,000 sh (-1.05%)
Diamond Hill Capital 346,336 sh (-37.93%)
Ruane Cunniff 275,963 sh (-38.19%)
» More
» Details

Insider Trades

Latest Guru Trades with VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:OPK, NYSE:MNK, OTCPK:IPSEY, OTCPK:HYPMY, OTCPK:HKMPF, NYSE:TARO, OTCPK:HLUYY, NAS:NBIX, OTCPK:SFOSF, NYSE:RDY, NYSE:PTHN, NAS:ENDP, NAS:HZNP, NYSE:CTLT, OTCPK:INVVY, NAS:AKRX, NAS:MDCO, NAS:IRWD, NAS:RDUS, OTCPK:APNHY » details
Traded in other countries:VRX.Canada, BVF.Germany, VRX N.Mexico, VRX.Switzerland, 0QYW.UK,
Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.

Valeant Pharmaceuticals International Inc was formed under the Business Corporations Act (Ontario) on February 18, 2000, as a result of the amalgamation of TXM Corporation and Biovail Corporation International. Biovail was continued under the Canada Business Corporations Act effective June 29, 2005. In connection with the acquisition of Valeant Pharmaceuticals International (Valeant) in September 2010, Biovail was renamed Valeant Pharmaceuticals International, Inc. It is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter products OTC, and medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices, which are marketed directly or indirectly in over 100 countries. The Company operates in two segments; Developed Markets and Emerging Markets. In the Developed Markets segment, it focuses its efforts in the eye health, dermatology, and neurology therapeutic classes. The Developed Markets segment consists of four reporting units based on geography, namely; U.S., Canada and Australia, Western Europe, and Japan. In the Emerging Markets segment, it focuses on branded generics, OTC products, and medical devices. The Emerging Markets segment consists of three reporting units based on geography, namely; Central & Eastern Europe, Middle East and North Africa, Latin America, and Asia & South Africa. Its principal pharmaceutical products are; Wellbutrin XL, Xenazine, Zovirax Cream, Zovirax, Lotemax, Arestin and Prolensa. Its principal OTC products are; PreserVision, ReNu Multiplus, Ocuvite, Artelac, and CeraVe. The Company relies on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of its technology and business. Its top four geographic markets are; the U.S. and Puerto Rico, Canada, Poland and Russia. The Company competes with specialty and other pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, the EU and in other countries in which it market its products. The principal raw materials, including active pharmaceutical ingredient, used by the Company or its third party manufacturers for its various products are purchased in the open market or are otherwise available from several sources. The Company is subject to extensive U.S. federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulation in Canada and similar regulations in foreign countries in which it may conduct its business.

Ratios

vs
industry
vs
history
Forward P/E 2.68
VRX's Forward P/E is ranked higher than
98% of the 63 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.41 vs. VRX: 2.68 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 10.35
VRX's Price/Owner Earnings (ttm) is ranked higher than
89% of the 280 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.53 vs. VRX: 10.35 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
VRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.26  Med: 17.41 Max: 805.48
Current: 10.35
4.26
805.48
P/B 1.32
VRX's P/B is ranked higher than
79% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. VRX: 1.32 )
Ranked among companies with meaningful P/B only.
VRX' s P/B Range Over the Past 10 Years
Min: 1.03  Med: 2.88 Max: 14.44
Current: 1.32
1.03
14.44
P/S 0.51
VRX's P/S is ranked higher than
91% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. VRX: 0.51 )
Ranked among companies with meaningful P/S only.
VRX' s P/S Range Over the Past 10 Years
Min: 0.5  Med: 3.94 Max: 10.5
Current: 0.51
0.5
10.5
PFCF 3.02
VRX's PFCF is ranked higher than
96% of the 197 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.94 vs. VRX: 3.02 )
Ranked among companies with meaningful PFCF only.
VRX' s PFCF Range Over the Past 10 Years
Min: 2.67  Med: 13.41 Max: 450.3
Current: 3.02
2.67
450.3
POCF 2.55
VRX's POCF is ranked higher than
95% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.41 vs. VRX: 2.55 )
Ranked among companies with meaningful POCF only.
VRX' s POCF Range Over the Past 10 Years
Min: 2.46  Med: 10.88 Max: 47.76
Current: 2.55
2.46
47.76
EV-to-EBITDA 12.28
VRX's EV-to-EBITDA is ranked higher than
68% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.70 vs. VRX: 12.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31  Med: 13.95 Max: 106.7
Current: 12.28
-31
106.7
Current Ratio 1.46
VRX's Current Ratio is ranked lower than
73% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. VRX: 1.46 )
Ranked among companies with meaningful Current Ratio only.
VRX' s Current Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.62 Max: 9.68
Current: 1.46
0.72
9.68
Quick Ratio 1.12
VRX's Quick Ratio is ranked lower than
70% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. VRX: 1.12 )
Ranked among companies with meaningful Quick Ratio only.
VRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.25 Max: 9.3
Current: 1.12
0.59
9.3
Days Inventory 174.85
VRX's Days Inventory is ranked lower than
76% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.28 vs. VRX: 174.85 )
Ranked among companies with meaningful Days Inventory only.
VRX' s Days Inventory Range Over the Past 10 Years
Min: 115.82  Med: 140.68 Max: 174.85
Current: 174.85
115.82
174.85
Days Sales Outstanding 97.51
VRX's Days Sales Outstanding is ranked lower than
65% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.78 vs. VRX: 97.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.41  Med: 75.58 Max: 106.05
Current: 97.51
43.41
106.05
Days Payable 48.43
VRX's Days Payable is ranked lower than
69% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.88 vs. VRX: 48.43 )
Ranked among companies with meaningful Days Payable only.
VRX' s Days Payable Range Over the Past 10 Years
Min: 48.43  Med: 80.02 Max: 120.5
Current: 48.43
48.43
120.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.10
VRX's 3-Year Average Share Buyback Ratio is ranked higher than
52% of the 435 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. VRX: -4.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.7  Med: -3.3 Max: 14
Current: -4.1
-34.7
14

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.30
VRX's Price/Projected FCF is ranked higher than
98% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.77 vs. VRX: 0.30 )
Ranked among companies with meaningful Price/Projected FCF only.
VRX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.29  Med: 1.84 Max: 11.22
Current: 0.3
0.29
11.22
Price/Median PS Value 0.14
VRX's Price/Median PS Value is ranked higher than
98% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. VRX: 0.14 )
Ranked among companies with meaningful Price/Median PS Value only.
VRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 1.41 Max: 5.21
Current: 0.14
0.13
5.21
Earnings Yield (Greenblatt) (%) -1.50
VRX's Earnings Yield (Greenblatt) (%) is ranked lower than
74% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. VRX: -1.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.5  Med: 3 Max: 22.8
Current: -1.5
-1.5
22.8
Forward Rate of Return (Yacktman) (%) 72.96
VRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
98% of the 344 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.15 vs. VRX: 72.96 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
VRX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 2.5  Med: 17.1 Max: 84.9
Current: 72.96
2.5
84.9

More Statistics

Revenue (TTM) (Mil) $10,029
EPS (TTM) $ -6.58
Beta-1.02
Short Percentage of Float11.27%
52-Week Range $13.77 - 119.87
Shares Outstanding (Mil)347.67

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 12,833 12,670 13,128 13,700
EPS ($) 7.21 7.77 9.94 11.43
EPS w/o NRI ($) 7.21 7.77 9.94 11.43
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NYSE:VRX

Headlines

Articles On GuruFocus.com
24 Questions With Value Investor Jacob Taylor of the UC Davis Graduate School of Management Dec 06 2016 
Valeant, Salix, Sales Force and Asset Sales Nov 30 2016 
Ackman Sticks With Valeant as a Deleverage Story Nov 21 2016 
Valeant and Philidor After the Criminal Charges Nov 18 2016 
Lou Simpson Goes 2-for-2 in 3rd Quarter Nov 14 2016 
Bill Ackman: Valeant Diversified Pharma Business a Buffett ‘Cigar Butt’ Nov 10 2016 
Mylan Posts Loss Amid Investigation, Settlement Nov 10 2016 
How to Avoid the Same Mistakes Your Heroes Made Nov 10 2016 
Allergan: Trading at a Low Earnings Multiple Nov 06 2016 
Bill Ackman Slumps Further in October Nov 02 2016 

More From Other Websites
Can Donald Trump Make Valeant Stock Great Again? (VRX, XLV) Dec 05 2016
Is Valeant Pharmaceuticals Intl Inc (VRX) A Good Stock To Buy? Dec 04 2016
[$$] Week in Review, December 2 Dec 02 2016
Analysts Are Bullish on Valeant Dec 02 2016
Bill Ackman’s Biggest Q3 Moves As He Seeks Elusive Turnaround Dec 02 2016
Ackman Scores Big November on Fannie, Freddie Gains Dec 02 2016
Is Valeant Exposed to Default Risk? Dec 02 2016
Yes, There Will Be Margin Erosion for Valeant in 2017 Dec 02 2016
What’s Forcing Valeant to Sell Its Core Assets? Dec 01 2016
How Does Valeant Plan to Resume Growth beyond 2016? Dec 01 2016
Chou Associates REALLY Loves Its Portfolio, Because It Didn’t Touch It Last Quarter Dec 01 2016
Why Wasn’t Valeant’s Enormous Growth Sustainable? Dec 01 2016
Ranking the Activists for Proxy Season 2016 Dec 01 2016
Valeant Stock Plunges 11% on Failed Salix Sale (VRX) Dec 01 2016
Is Computer Sciences Corporation (CSC) A Good Stock To Buy? Dec 01 2016
SEC Discloses Correspondence Over Valeant's Accounting Practices Nov 30 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)